Preclinical & Clinical Pharmacology & Therapeutics for A
Preclinical & Clinical Pharmacology & Therapeutics for A
批准号:
6756785
负责人:
JEAN GREM
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
adenocarcinoma antineoplastics clinical trials colorectal neoplasms combination chemotherapy drug administration rate /duration drug design /synthesis /production drug screening /evaluation fluorouracil gastrointestinal neoplasms human subject human therapy evaluation neoplasm /cancer chemotherapy neoplasm /cancer genetics neoplasm /cancer pharmacology patient oriented research pharmacokinetics prognosis tissue /cell culture
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Innovative strategies are needed to improve the prognosis of patients with adenocarcinomas arising in the gastrointestinal tract. We are studying the interaction of modulatory & cytotoxic agents with fluorouracil in vitro to define optimal sequences for potential clinical use. Studies are designed to elucidate the optimal schedule of administration & mechanism of action of novel agents with activity against colon cancer cell lines to facilitate their rational clinical use. We implement clinical trials that incorporate clinical pharmacokinetic, biochemical &/or molecular endpoints. New analytic assay methods are developed to measure the pharmacokinetics & intracellular pharmacodynamics of the anticancer agents. Our goal is to develop new agents & drug combinations for patients with GI cancers, & to develop strategies that selectively target cancer cells with genomic instability &/or impaired programmed cell death pathways.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PRECLINICAL & CLINICAL PHARMACOLOGY & THERAPEUTICS FOR ADENOCARCINOMAS ARISING IN
-
批准号:6290790
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:JEAN GREM
-
依托单位:
Preclinical & Clinical Pharmacology & Therapeutics for Adenocarcinomas Arising i
-
批准号:6433377
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:JEAN GREM
-
依托单位:
Clinical Pharmacology & Therapeutics for Adenocarcinoma
-
批准号:6558392
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:JEAN GREM
-
依托单位:
海外基金